与脂质纳米颗粒结合的阿迪波涅丁mRNA特别针对2型糖尿病的致病性
Rady E El-Araby1,2, Qisheng Tu1, Ying Xie1
1Division of Oral Biology, Tufts University School of Dental Medicine, Boston, MA 02111, USA.
Aging and disease
|June 25, 2024
概括
这项研究表明,脂质纳米粒子输送的阿迪波涅克丁 (APN) mRNA可以增加APN水平,改善胰岛素抵抗和高血糖在2型糖尿病 (T2D) 的小鼠模型. 这种核酸疗法为T2D治疗提供了一个有前途的新途径.
科学领域:
- 代谢性疾病研究研究.
- 分子医学是分子医学.
- 基因治疗是一种基因疗法.
背景情况:
- 2型糖尿病 (T2D) 是由胰岛素抵抗驱动的全球健康问题.
- 平素 (APN) 水平与肥胖,胰岛素抵抗和体重指数相反相关.
- 目前的T2D治疗需要有效的策略来管理这种情况及其并发症.
研究的目的:
- 研究使用脂质纳米颗粒 (LNP) 提高内源性皮素 (APN) 水平的潜力,用于APN mRNA输送.
- 评估APN mRNA-LNP治疗在T2D的饮食诱导肥胖 (DIO) 鼠标模型中的治疗效果.
主要方法:
- 将APN mRNA与脂质纳米颗粒 (LNP) 结合给DIO小鼠.
- 在治疗后的各种组织中评估APN合成.
- 评估代谢参数,包括体重,葡萄糖水平,胰岛素敏感性和功能.
主要成果:
- APN mRNA-LNP治疗成功诱导了多种组织的 APN 合成.
- 治疗可以预防体重增加,通过Glut-4改善高血糖,并通过阻断EGFR缓解糖尿病病.
- 通过DGKd激活和PKCε抑制观察到增强的胰岛素敏感性,恢复胰岛素受体功能并刺激胰岛素分泌.
结论:
- APN mRNA-LNP疗法有效地增加了阿迪波涅克丁水平,并证明了T2D的显著治疗益处.
- 这种方法显示了对2型糖尿病综合治疗策略的潜力.
- 使用APN mRNA-LNPs的基于核酸的疗法代表了T2D管理中的一个有前途的前沿.
相关概念视频
01:24Glucagon-like Receptor Agonists
316
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
316
01:22Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
01:28Insulin: The Receptor and Signaling Pathways
1.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K
01:22Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K